A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults
← catalyst calendarNCT07444294 · readout in 120 d
Sponsored by Scholar Rock, Inc. (industry) · SRRK — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
76estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-21 | actual | When the study began enrolling |
| Primary completion | 2026-12-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-09 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: Placebo
- Drug: SRK-439
- Drug: SRK-439
Primary outcomes
what the primary-completion date above is the date OFEvaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants
measured Up to 32 weeks
Permalink · SRRK's whole pipeline · Catalyst calendar · Every registered study · What changed